OM Pharma

OM Pharma
Company typeSociété Anonyme
IndustryBiopharmaceutical
FoundedBarcelona, (1930)
HeadquartersGeneva, Switzerland
Area served
Worldwide
Key people
  • Roch Ogier (CEO)
Products
OM-89
OwnerEtienne Jornod (Executive Chairman & Co‑Owner)
Websitewww.ompharma.com

OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.

OM Pharma was established in Barcelona in 1930 and relocated its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French pharmacist. In 2020, the company became part of Optimus Holding, led by Etienne Jornod.[1]

The company specializes in developing and commercializing bacterial lysate-based products designed to help prevent respiratory and urinary tract infections by enhancing the immune system. Its research pipeline includes future applications of lysates.[2]

In 2021, OM Pharma received the Geneva Economy Award.[3]

History

Integration into CSL Vifor/Galenica

In 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group.[4][5][6]

Acquisition by Optimus Holding

In 2020, OM Pharma was acquired by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod with a consortium of inverstors.[7] As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities.[8] Since 2024, Roch Ogier has served as the company’s CEO.[9]

Structure and subsidiaries

OM Pharma employs over 400 people, with its global headquarters and biotech campus located in Meyrin, Geneva, and an affiliate in Villars-sur-Glâne, Fribourg.[10]

The company also operates in Peru through an affiliate in Lima and maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.[11][12]

Products

OM Pharma’s products include:

  • Broncho-Vaxom (OM-85) indicated for the prevention of recurrent respiratory tract infections [13][14]. With continued research on asthma prevention in high-risk infants[15]
  • Uro-Vaxom (OM-89) indicated for the prevention of recurrent urinary tract infections [16]
  • Doxium (calcium dobesilate) indicated in treatment of microangiopathies, signs of chronic venous insufficiencies in the lower limbs, diabetic retinopathy and hemorrhoidal syndrome[17][18]
  • Dicynone (etamsylate) indicated in the treatment of capillary hemorrhages [19]

References

  1. ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 18 September 2020. ISSN 1423-3967. Retrieved 30 October 2024.
  2. ^ Ogier, Roch; Kherad, Omar; Balavoine, Michael (22 January 2025). "Le travail de l'industrie pharmaceutique reste largement méconnu". Rev Med Suisse (in Swiss French). 902: 116–118.
  3. ^ "OM Pharma Wins Geneva Economy Award". PharmExec. 21 September 2021. Retrieved 13 November 2024.
  4. ^ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in French). 8 September 2009. ISSN 1423-3967. Retrieved 1 November 2024.
  5. ^ "BioAlps | 20 years of innovation | OM Pharma". BioAlps. 20 October 2021. Retrieved 30 October 2024.
  6. ^ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in French). 9 November 2017. Retrieved 1 November 2024.
  7. ^ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  8. ^ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 30 October 2024.
  9. ^ "La Gazette du Laboratoire – OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 1 November 2024.
  10. ^ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  11. ^ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 30 October 2024.
  12. ^ "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in Spanish). 3 May 2023. Retrieved 1 November 2024.
  13. ^ Yin, Ju; Xu, Baoping; Zeng, Xiantao; Shen, Kunling (1 January 2018). "Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis". International Immunopharmacology. 54: 198–209. doi:10.1016/j.intimp.2017.10.032. ISSN 1567-5769.
  14. ^ "OM85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?". medicine.uq.edu.au. 11 June 2020. Retrieved 14 August 2025.
  15. ^ "(ORBEX) Randomized, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of Oral Bacterial Extract for the prevention of wheezing lower respiratory tract illness". airways.uahs.arizona.edu. Retrieved 14 August 2025.
  16. ^ Brodie, Andrew; El-Taji, Omar; Jour, Ibrahim; Foley, Charlotte; Hanbury, Damian (October 2020). "A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections". Current Urology. 14 (3): 130–134. doi:10.1159/000499248. ISSN 1661-7649. PMC 7659410. PMID 33224005.
  17. ^ Allain, Herv??; Ramelet, Albert A; Polard, Elisabeth; Bentu??-Ferrer, Dani??le (2004). "Safety of Calcium Dobesilate in Chronic Venous Disease, Diabetic Retinopathy and Haemorrhoids". Drug Safety. 27 (9): 649–660. doi:10.2165/00002018-200427090-00003. ISSN 0114-5916.
  18. ^ Liu, Jie; Li, Shulin; Sun, Dong (15 March 2019). "Calcium Dobesilate and Micro-vascular diseases". Life Sciences. 221: 348–353. doi:10.1016/j.lfs.2019.02.023. ISSN 1879-0631. PMID 30769115.
  19. ^ Garay, Ricardo P.; Chiavaroli, Carlo; Hannaert, Patrick (2006). "Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent". American Journal of Therapeutics. 13 (3): 236–247. doi:10.1097/01.mjt.0000158336.62740.54. ISSN 1075-2765. PMID 16772766.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.